Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS (NKTR)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 04/23 09:38:42 pm
85.505 USD   -0.82%
04/16S&P 500 MOVERS : Nktr, jbht
AQ
04/11NEKTAR THERAPEU : Announces Dosing of First Patient in Phase 1/2 Cli..
PR
04/10S&P 500 MOVERS : Nktr, stx
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : Today’s Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2018 | 02:27pm CEST

NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Nektar shares closed lower on Monday as the company is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2018. Shares of Merck were sailing higher on positive clinical trial results of its Keytruda with chemotherapy.

RDI Initiates Coverage on:

Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR

Merck & Co., Inc.
https://rdinvesting.com/news/?ticker=MRK

Nektar Therapeutics shares closed down 7% on Monday on about 7.1 million shares traded. The company announced over the weekend that it would announce new preclinical data for its immuno-oncology programs at the American Association for Cancer Research Annual Meeting 2018. The company said it would be releasing new preclinical data on NKTR-214, a CD122 biased agonist, and NKTR-262, a novel toll-like receptor agonist, by company researchers and collaborators. Chief Scientific Officer as well as Senior Vice President of the company, Jonathan Zalevsky, Ph.D. remarked, "The preclinical studies being presented at AACR by both Nektar scientists and our collaborators highlight the potential of NKTR-214 as a backbone therapy in immuno-oncology. NKTR-214 is designed to stimulate the number and functional activity of cancer-fighting T cells which are often limited in patients with cancer and necessary for immunotherapy to be fully effective. These data show that NKTR-214 synergizes with multiple modalities including TLRs, HDAC and ACT. With regard to TLR biology, the combination of NKTR-214 and NKTR-262 engages both the innate and adaptive immune system to initiate antigen release, expand T cells and drive them into the tumor. This novel immuno-oncology combination is now being evaluated in a Phase 1/2 study."

Access RDI's Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR

Merck & Co., Inc. shares closed up 2.59% yesterday on about 22.5 million shares traded. The stock was soaring in the green after the company released late-stage clinical trial results that revealed a cancer drug combination that uses its blockbuster drug Keytruda had reduced patients' risk of death by 51%. The company was making headlines as Immunotherapy Keytruda along with chemotherapy had significantly improved the overall survival in newly-diagnosed patients with advanced non-small cell lung cancer. The results were released the same day Bristol-Myers Squibb also released positive lung cancer data for its immunotherapy combination however shares of Britsol plummeted on the news. According to Credit Suisse analyst Vamil Divan, "Merck appears to be the clear winner so far." According to Divan, the Merck data was better than expected across all patient subgroups, while questions remain about Bristol's Opdivo and Yervoy combination "until we see full data."

Access RDI's Merck & Co., Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MRK

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and Merck & Co., Inc. (NYSE: MRK) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


© Accesswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
04/17NEKTAR THERAPEUTICS : Today’s Research Reports on Stocks to Watch: Nektar Therap..
AC
04/16S&P 500 MOVERS : Nktr, jbht
AQ
04/12NEKTAR THERAPEUTICS : Announces Dosing of First Patient in Phase 1/2 Clinical St..
AQ
04/11NEKTAR THERAPEUTICS : Announces Dosing of First Patient in Phase 1/2 Clinical St..
PR
04/10S&P 500 MOVERS : Nktr, stx
AQ
04/09Biotech struggles as 2Q opens
AQ
04/06S&P 500 MOVERS : Incy, ulta
AQ
04/03NEKTAR THERAPEUTICS : Announces Effective Date of Global Development & Commercia..
PR
04/03NEKTAR THERAPEUTICS : Other Events (form 8-K)
AQ
03/15NEKTAR THERAPEUTICS : Patent Issued for N-Optionally Substituted Aryl-2-Oligomer..
AQ
More news
News from SeekingAlpha
04/22ROUNDS REPORT : Solid Biosciences Is Making A Comeback While Improving FDA Polic.. 
04/17Have I Got A Biotech Stock For You 
04/16Syria Tensions Hit Russia Stocks And Help Defense Stocks, And Netflix Perks U.. 
04/16WALL STREET BREAKFAST : Russia, Ruble, Sanctions 
04/15GERON CORPORATION : How The Improved Industry Tailwinds Can Help Imetelstat 
Financials ($)
Sales 2018 540 M
EBIT 2018 57,2 M
Net income 2018 27,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 86 210,00
P/E ratio 2019
Capi. / Sales 2018 25,7x
Capi. / Sales 2019 43,0x
Capitalization 13 873 M
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 103 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS44.36%13 873
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
ALNYLAM PHARMACEUTICALS, INC.-23.27%9 765